prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Her2, PAIIENI MISTOKY: The patient is. a -year-old female. Clinical history is not provided Site Code : breast, lower inner quadrant. PRE-OP DIAGNOSIS: Left breast cancer. POST-OP DIAGNOSIS: Same. PROCEDURE: Left total mastectomy. +$. ADDENDA: Addendum. Fluorescence in situ hybridization analysis was performed on block 1D using the DNA probe for Her-2/neu gene. The. ratio of Her-2/neu gene signals to chromosome 17 centromere signals was determined to be 2.05. Therefore, the. interpretation is: borderline amplification of the Her-2/neu gene. que. ves. My signature is attestation that I have personally reviewed the submitted materiali. Addendum. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controls, the test for the presence of these hormone receptor proteins is. performed by the immunoperoxidase method, and reported according to the consensus statement on adjuvant. therapy for breast cancer, of. A positive ER or PR tumor shows any nuclear immunostaining, and is. semiquantitated as indicated below. Semiquantitative Statement. ER positive. Percent cells staining as: (0 95%; 1+ 5%, 2+ 0%, 3+ 0%). PR negative. Percent cells staining as: (0 100%, 1+ 0%, 2+ 0%, 3+ 0%). HER-2/NEU DAKO HERCEPTEST: A WEAK TO MODERATE COMPLETE MEMBRANE STAINING IS OBSERVED IN MORE. THAN 10% OF THE TUMOR CELLS. HER-2/NEU IS INTERPRETED AS WEAKLY POSITIVE ISCORE 2+I. NOTE: Her-2/Neu FISH was ordered and will be subsequently reported. The Her-2/neu and estrogen/progesterone receptor assays were performed with FDA approved. methods. FIÑAL DIAGNOSIS: PART 1: LEFT BREAST, TOTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA, 2.0 CM, NOTTINGHAM SCORE 7/9 (tubules 3, nuclei 2, mitosis 2),. LOCATED IN THE LOWER INNER QUADRANT AND EXTENDING TO THE LOWER OUTER QUADRANT. B. TUMOR COMES TO WITHIN 0,1 CM FROM THE INNER LOWER OF QUADRANT MARGIN. C. MICROCALCIFICATION ASSOCIATED WITH TUMOR. D. DUCTAL CARCINOMA IN SITU, NUCLEAR GRADE 2, SOLID TYPE WITH COMEDO NECROSIS,. REPRESENTING 10-15% OF THE TUMOR VOLUME. E. MARGINS FREE OF TUMOR. F. REMAINING BREAST TISSUE WITH FIBROCYSTIC CHANGES, SCLEROSING ADENOSIS AND. MICROCALCIFICATION. G. SKIN AND NIPPLE NOT REMARKABLE. H. THREE LYMPH NODES NEGATIVE FOR TUMOR. PART 2: LEFT AXILLA, SENTINEL LYMPH NODE #1, EXCISIONAL BIOPSY. ONE LYMPH NODE NEGATIVE FOR TUMOR, CONFIRMED BY NEGATIVE AE1/AE3 IMMUNOSTAIN. PART 3: LEFT AXILLA, SENTINEL LYMPH NODE #2, EXCISIONAL BIOPSY -. ONE LYMPH NODE NEGATIVE FOR TUMOR, CONFIRMED BY NEGATIVE AE1/AE3 IMMUNOSTAIN. COMMENT: Estrogen and Progesterone receptors and HER-2/Neu will be performed on block 1D and the result will follow in a. separate report.

expanded version (tokens=1240) : 
 The following information can be extracted from the breast pathology report:

- Histological classification: The patient has infiltrating ductal carcinoma and ductal carcinoma in situ.
- Subtype: The subtype of the cancer is HER2-positive.
- Necrosis: The ductal carcinoma in situ component has comedo necrosis.
- Tumor infiltrating lymphocytes: There is no mention of tumor infiltrating lymphocytes in the report.
- Histological grade: The Nottingham score is 7 out of 9 (tubules 3, nuclei 2, mitosis 2).
- Nuclear grade: The nuclear grade of the ductal carcinoma in situ component is 2.
- Lymphovascular invasion: There is no mention of lymphovascular invasion in the report.
- Calcification: There is microcalcification associated with the tumor.
- Receptor status: The estrogen and progesterone receptor status has not been reported yet, but it will be performed on block 1D and reported in a separate report. The HER2/neu status is weakly positive, with a score of 2+.
- IHC and ancillary testing results: Fluorescence in situ hybridization analysis showed borderline amplification of the HER2/neu gene. Immunoperoxidase staining for estrogen and progesterone receptors will be reported separately. Negative AE1/AE3 immunostain confirmed that one sentinel lymph node in the left axilla was negative for tumor. 

Additional information includes

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1388) : 
 Report: The patient, a year-old female, was diagnosed with HER2-positive infiltrating ductal carcinoma and ductal carcinoma in situ in the left breast. The tumor size was 2.0 cm with microcalcification, and one sentinel lymph node was negative for tumor. The estrogen and progesterone receptor status is pending, while the HER2/neu status was weakly positive with borderline amplification. The report does not mention any lymphovascular invasion or tumor infiltrating lymphocytes.

